1-4 of 4
Koji Isobe
Close
Sort by
Journal Articles

The Genotype Combination of the P2Y12 Gene Might Confer Greater Risk for Coronary Artery Disease.

Koji Isobe, Yumiko Matsubara, PhD, Shinichi Takahashi, Toshihiro Uchida, Hiroaki Ishihara, PhD, Toshiro Shibano, PhD, Mie Ishikawa, MD, Kenichi Matsushita, MD, Shiro Iwanaga, MD, Satosh Ogawa, MD, Gentaro Watanabe, MD, Yasuo Ikeda, MD PhD, Mitsuru Murata, MD PhD
Journal: Blood
Blood (2006) 108 (11): 1468.
https://doi.org/10.1182/blood.V108.11.1468.1468
Published: 2006
Journal Articles

The Genotypic Combination of Homozygous Carriers of Both H1 Haplotype and 34C Shows a Significantly Lower Responsiveness to ADP-Induced Platelet Aggregation Than Others in Healthy Volunteers.

Koji Isobe, Yumiko Matsubara, MD, Shinichi Takahashi, Miho Iwashita, Risa Komine, Aya Shimizu, Toshihiro Uchida, Hiroaki Ishihara, PhD, Toshiro Shibano, PhD, Gentaro Watanabe, MD, Yasuo Ikeda, MD, Mitsuru Murata, MD
Journal: Blood
Blood (2005) 106 (11): 3560.
https://doi.org/10.1182/blood.V106.11.3560.3560
Published: 2005
Journal Articles

Antithrombotic and Hemorrhagic Effects of DU-176b, a Novel, Potent and Orally Active Direct Factor Xa Inhibitor: A Wider Safety Margin Compared to Heparins and Warfarin.

Taketoshi Furugohri, Yuko Honda, Chikako Matsumoto, Koji Isobe, Nobutoshi Sugiyama, PhD, Yoshiyuki Morishima, PhD, Toshiro Shibano, PhD
Journal: Blood
Blood (2004) 104 (11): 1851.
https://doi.org/10.1182/blood.V104.11.1851.1851
Published: 2004
Journal Articles

In Vitro Characteristics, Anticoagulant Effects and In Vivo Antithrombotic Efficacy of a Novel, Potent and Orally Active Direct Factor Xa Inhibitor, DU-176b.

Yoshiyuki Morishima, PhD, Taketoshi Furugohri, Koji Isobe, Yuko Honda, Chikako Matsumoto, Yoko Shiozaki, Sumie Muramatsu, Nobutoshi Sugiyama, PhD, Toshiro Shibano, PhD
Journal: Blood
Blood (2004) 104 (11): 1862.
https://doi.org/10.1182/blood.V104.11.1862.1862
Published: 2004